Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: A phase I trial of safety and immune activation

Journal of Clinical Oncology

Volumn 19, Issue 1, 2001, Pages 145-156

  Jaffee, E M ^a   Hruban, R H ^a   Biedrzycki, B ^a   Laheru, D ^a   Schepers, K ^a   Sauter, P R ^a   Goemann, M ^a   Coleman, J ^a   Grochow, L ^a   Donehower, R C ^a   Lillemoe, K D ^a   O'Reilly, S ^a   Abrams, R A ^a   Pardoll, D M ^a   Cameron, J L ^a   Yeo, C J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; TUMOR VACCINE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGRESSION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DELAYED HYPERSENSITIVITY; DOSE RESPONSE; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; HUMAN; IMMUNE RESPONSE; JOINT STIFFNESS; MALE; PANCREAS ADENOCARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SKIN ULCER; SURVIVAL TIME;

EID: 0035152718     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.1.145     Document Type: Article

References (42)

1. Cancer statistics
2. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: A randomized trial
3. Gemcitabine as a radiation sensitizer
4. Phase I trial of twice weekly gemcitabine and cuncurrent radiation in patients with advanced pancreatic cancer
5. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer
6. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant chemoradiation improves survival
7. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head
8. Cancer vaccines
9. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte/macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity
10. Bioactivity of human GM-CSF gene transduced autologous renal vaccines
11. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma
12. Induction of immunity to prostate cancer antigens: Results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer
13. Human tumor antigens recognized by T lymphocytes
14. Identification of the genes encoding cancer antigens: Implications for cancer immunotherapy
15. Identification of HLA-A2 restricted T-cell epitopes derived from the MUC-1 tumor antigen for broadly applicable vaccine therapies
16. + T cell lines from patients immunized with ras oncogene derived peptides reflecting codon 12 mutations
17. Potential role of tumor vaccines in GI malignancies
18. The role of bone marrow derived cells in presenting MHC class I-restricted tumor antigens
19. In vivo cross-priming of MHC class I-restricted antigens requires TAP transporter
20. Protective antitumor immunity induced by immunization with completely allogeneic tumor cells
21. Vaccination with allogeneic tumor cells induces specific antitumor immunity
22. Development and characterization of a cytokine secreting pancreatic adenocarcinoma vaccine from primary tumors for use in clinical trials
23. A phase I trial of lethally irradiated allogeneic pancreatic tumor cells transfected with the GM-CSF gene for the treatment of pancreatic adenomacarcinoma
24. Measurement of delayed skin test responses
25. Renal cell carcinoma treated by vaccines for active specific immunotherapy: Correlation of survival with skin testing by autologous tumor cells
26. Delayed cutaneous hypersensitivity reactions to membrane extracts of human tumor cells
27. Delayed cutaneous hypersensitivity to autologous tumor cells in colorectal cancer patients immunized with an autologous tumor cell: Bacillus Calmette-Guerin vaccine
28. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide
29. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: Clinical and immunologic results in 64 patients
30. Design and analysis of phase I clinical trials
31. Pancreaticoduodenectomy with or without extended retroperitoneal lymphadenectomy for periampullary adenocarcinoma
32. Transient acantholytic dermatosis: A reevaluation
33. Grover's disease: Clinicopathologic review of 72 cases
34. Transient acantholytic dermatosis (Grover's disease): A global perspective
35. Immunodepression after major surgery in normal patients
36. Partial recovery of lymphocyte activity in patients with colorectal carcinoma after curative surgical treatment and return of plasma glutamate concentrations to normal levels
37. The influence of surgical operations on components of the human immune system
38. + T cells in the antitumor immune response
39. Dendritic cells and immune-based therapies
40. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines
41. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part 1)
42. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (part 2)